A new initiative is aiming to improve antibiotic stewardship in Kyrgyzstan’s primary care settings through innovative tools and strategies targeting respiratory tract infections (RTIs). Sponsored by Rigshospitalet, Denmark, the International Centre for Antimicrobial Resistance Solutions (ICARS), and the University of Copenhagen, this study combines diagnostic precision with patient education to reduce unnecessary antibiotic use.
In this article:
What are CRP testing and patient information leaflets?
The study integrates C-reactive protein point-of-care testing (CRP-POCT) alongside tailored patient information leaflets. CRP-POCT is a diagnostic tool used in primary care to measure inflammation levels, helping physicians distinguish bacterial from viral infections. By promoting evidence-based prescribing, the test minimizes indiscriminate use of antibiotics, which is crucial in the fight against antimicrobial resistance (AMR).
Patient information leaflets complement this diagnostic tool. These materials educate individuals about RTIs, their likely causes, and when antibiotics might be necessary. The combination of testing and education empowers both physicians and patients to make informed treatment decisions, promoting rational antibiotic use.
How does this approach target respiratory tract infections?
Respiratory tract infections, whether bacterial or viral, are often mismanaged due to diagnostic uncertainty. Bacterial cases require targeted antibiotic therapy, while viral infections do not. This distinction is critical in regions like Kyrgyzstan, where misuse of antibiotics amplifies AMR challenges.
CRP-POCT offers an objective, measurable way to assess whether inflammation levels indicate bacterial infection. Coupled with leaflets, this method addresses two common issues: misunderstanding of infection types and treatment urgency.
Benefits to patients and clinicians
Patients gain clarity about their condition and why antibiotics may or may not be suitable. Clinicians, on the other hand, receive a decision-support tool that enhances diagnostic accuracy. Together, these interventions reduce unnecessary prescriptions, curbing AMR risks.
Which stakeholders are involved?
The initiative is spearheaded by key international and academic organizations:
- Rigshospitalet, Denmark: A leading research hospital contributing scientific expertise and infrastructure.
- International Centre for Antimicrobial Resistance Solutions (ICARS): Focused on policy and solutions related to AMR challenges globally.
- University of Copenhagen: Providing academic backing and analysis.
The collaboration supports primary care providers in Kyrgyzstan, aligning medical practices with global AMR reduction strategies.
FAQ
- What is the intended outcome of CRP testing in this study?
The goal is to support evidence-based prescribing, reducing unnecessary antibiotic use. - What conditions are included in the study?
The study focuses on bacterial and viral respiratory tract infections, inflammation, and AMR. - How are patient leaflets used?
Leaflets provide accessible information about RTIs and explain antibiotic use, promoting patient understanding. - What organizations are leading this study?
Rigshospitalet, ICARS, and the University of Copenhagen. - Where will the study take place?
In primary care settings across Kyrgyzstan.
Summary
This study represents a significant step in optimizing antibiotic treatments through CRP testing and patient education. It underscores global efforts against AMR while empowering both patients and clinicians in Kyrgyzstan.
Legal disclaimer
This content is for informational purposes and is not legal or regulatory advice. It should not replace professional consultation with qualified experts.
Full announcement
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07261969?term=medical+device